Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917974 | 0.76 | CYP2A6 (0.39) | CYP2E1CYP3A4CYP2D6CYP2C9CYP2B6 | |
| SCHEMBL918070 | 0.72 | KDM4E (0.35) | KDM4EPOLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14837200 | 0.72 | PARP1 (0.43) | KDM4ELMNAALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL917909 | 0.71 | PARP1 (0.39) | — | |
| SCHEMBL14836947 | 0.70 | PARP1 (0.39) | SMN1; SMN2KMT2A | |
| SCHEMBL917641 | 0.70 | PARP1 (0.38) | ALDH1A1 | |
| SCHEMBL14837487 | 0.69 | ACHE (0.40) | KDM4EPOLBALDH1A1HPGDMEN1 | |
| SCHEMBL27817302 | 0.69 | — | — | |
| SCHEMBL918714 | 0.68 | KDM4E (0.40) | KDM4EPOLBLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14837279 | 0.68 | L3MBTL1 (0.50) | POLBALDH1A1L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758864-B1 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for their preparation, and their use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | disclosed |
| EP-1758864-B1 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for their preparation, and their use as medicaments | SANOFI AVENTIS DEUTSCHLAND (DE) | 2013-04-10 | — | — | EP | disclosed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795278-B2 | Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof | SANOFI-AVENTIS DEUTSCHLAND GMBH (US) | 2010-09-14 | — | — | US | disclosed |
| CN-1968929-B | Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments | SANOFI AVENTIS DEUTSCHLAND | 2010-09-08 | — | — | CN | disclosed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-21 | — | — | US | disclosed |
| EP-1758864-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123687-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021462-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | PARP1, PARP2, PARP11 | KDM4E 2214/4885POLB 37/4885LMNA 452/4885 |
| US-20070142430-A1 | SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, AND METHODS FOR THE PRODUCTION AND USE THEREOF | PARP1, PARP2, PARP11 | KDM4E 2214/4885POLB 37/4885LMNA 452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.